Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sting agonists

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Research Partnership

- PMLiVE

Baxalta inks $1.6bn immuno-oncology deal with Symphogen

Comes as the company's takeover negotiations with Shire continue

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

- PMLiVE

Lucid behavioural change programmes recognised at PMEA

Agency wins awards for initiatives for AbbVieand Genzyme

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

AbbVie looks to put bronchiolitis awareness back on the agenda

Relaunches More Than a Cold campaign

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links